Read the latest news about the volunteer-centered clinical research organization of reference to pharmaceutical and biotechnology sponsors for managing central nervous system clinical trials and developing innovative treatments worldwide.
Today, the U.S. Food and Drug Administration approved Zurzuvae (zuranolone), the first oral medication indicated to treat postpartum depression (PPD) in adults. PPD is a major depressive episode that typically occurs after childbirth but can also begin during the later stages of pregnancy. Until now, treatment for PPD was only available as an IV injection given by a health care provider in certain health care facilities.
Pillar Clinical Research was instrumental in the conduction of the clinical trials that tested Zurzavae.
Sign up to receive updates, promotions, and sneak peaks of Swab Test.